Perrigo Offloads Infant Formula Unit to MeridianMade
PRGO sits 73% above its 52-week low of $9.225.
Summary
Perrigo agreed to sell its infant formula business to MeridianMade for up to $175 million, exiting a category that has weighed on the company since the 2022 recall of its baby formula. The deal includes $40 million in cash at closing and up to an additional $135 million in contingent milestone payments, and the transaction is expected to significantly reduce future capital-spending requirements. Perrigo will record a fourth-quarter non-cash impairment charge of $275 million to $375 million. The deal follows October 9 speculation that CVC Capital was evaluating a purchase of all of Perrigo, and a divestiture gives management a cleaner, more focused consumer-health story either way. Perrigo posted $1.02 billion in Q2 2026 sales and reaffirmed its full-year adjusted EPS outlook in August. The buyer's financing is among the next things to watch.
At the time of this announcement, PRGO was trading at $15.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $9.23 to $21.84. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.